JAB 21822
Phase 3Small molecule
JAB 21822 is one of 65 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
9
Total Trials
7
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
JAB 21822
AAllist Pharmaceuticals, Inc.
Phase 3
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Advanced or Metastatic NSCLC1 trial
Non-Small Cell Lung Cancer1 trial
Chemotherapy1 trial
Pancreatic Cancer1 trial
3 more indications
Other Solid Tumors1 trial
Drug Interactions1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JAB 21822. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAllist Pharmaceuticals, Inc.